Background Clinical trials and real-world studies revealed a spectrum of response to CGRP
(-receptor) monoclonal antibodies (mAbs) in migraine prophylaxis, ranging from no effect at …

The avenue of effective migraine therapies blocking calcitonin gene-related peptide (CGRP)
transmission is the successful outcome of 35 years of translational research. Developed …

Calcitonin gene-related peptide-targeted monoclonal antibodies (CGRP mAbs) are
increasingly being used as preventive treatments for migraine. Their effectiveness and …

Background Migraine preventive treatment with CGRP (− receptor) monoclonal antibodies
(mAbs) has a positive effect on patients' health-related quality of life (HRQoL). The German …

Background and objectives The identification of predictors of response to antiCGRP mAbs
could favor tailored therapies and personalized treatment plans. This study is aimed at …

Background Criteria, including clinical features and effective outcomes, for access and
persistence of novel but costly treatments may vary between countries, thus affecting the …

Background Several drugs are available for the preventive treatment of both episodic and
chronic migraine. The choice of which therapy to initiate first, second, or third is not …

Background Calcitonin gene-related peptide (CGRP)(receptor) antibodies (erenumab,
fremanezumab and galcanezumab) are increasingly used in prophylactic treatment of …

Background National and international guidelines recommend stopping migraine
prophylaxis with CGRP (-receptor) monoclonal antibodies after 6–12 months of successful …

Background CGRP Antibodies are high‐cost newly licensed migraine preventatives.
Objective To calculate the overall reduction in monthly migraine days and the proportion …